

Allergan plc
Form 8-K
December 20, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 20, 2016 (December 20, 2016)

ALLERGAN PLC

(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction

of incorporation)

001-36867
(Commission

File Number)

Clonshaugh Business and Technology Park

98-1114402
(I.R.S. Employer

Identification No.)

Edgar Filing: Allergan plc - Form 8-K

Coolock, Dublin, D17 E400, Ireland

(Address of Principal Executive Offices)

(862) 261-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On December 20, 2016, Allergan plc (Allergan) and Acelyt L.P. Inc. (Acelyt) issued a joint press release announcing the execution of a Stock Purchase Agreement (the Purchase Agreement), dated December 20, 2016, by and among Allergan Holdco US, Inc. (Allergan US), a Delaware corporation and a wholly owned subsidiary of Allergan, LifeCell Corporation (LifeCell), a Delaware corporation and a wholly owned subsidiary of Acelyt, and, solely for purposes of Section 4.20 of the Purchase Agreement, Warner Chilcott Limited, a Bermuda company. Pursuant to the Purchase Agreement, Acelyt will sell to Allergan US, and Allergan US will purchase for cash from Acelyt, all of the outstanding shares of common stock of LifeCell. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
99.1	Joint Press Release dated December 20, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allergan plc

Date: December 20, 2016

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: Chief Legal Officer and Corporate Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Joint Press Release dated December 20, 2016.